Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Accenture
Baxter
Queensland Health
AstraZeneca
Farmers Insurance
UBS
Healthtrust
Medtronic

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022173

« Back to Dashboard

NDA 022173 describes ZYPREXA RELPREVV, which is a drug marketed by Eli Lilly Co and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the ZYPREXA RELPREVV profile page.

The generic ingredient in ZYPREXA RELPREVV is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.
Summary for 022173
Tradename:ZYPREXA RELPREVV
Applicant:Eli Lilly Co
Ingredient:olanzapine pamoate
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022173
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173 NDA Eli Lilly and Company 0002-7635 N 0002-7635-11
ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173 NDA Eli Lilly and Company 0002-7636 N 0002-7636-11

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION, EXTENDED RELEASE;INTRAMUSCULARStrengthEQ 210MG BASE/VIAL
Approval Date:Dec 11, 2009TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 30, 2018Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION, EXTENDED RELEASE;INTRAMUSCULARStrengthEQ 300MG BASE/VIAL
Approval Date:Dec 11, 2009TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 30, 2018Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION, EXTENDED RELEASE;INTRAMUSCULARStrengthEQ 405MG BASE/VIAL
Approval Date:Dec 11, 2009TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 30, 2018Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

Expired US Patents for NDA 022173

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Chubb
Argus Health
Teva
Federal Trade Commission
US Army
Chinese Patent Office
Julphar
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.